Hepatic Steatosis Diagnosis and Pathophysiology

Diagnostic Criteria and Metabolic Context

The American Association for the Study of Liver Diseases recommends that evidence of hepatic steatosis must be demonstrated either by imaging or by histology showing ≥5% fat accumulation, and exclusion of secondary causes, including significant alcohol consumption and long-term steatogenic medications, to establish the diagnosis of hepatic steatosis in the context of metabolic dysfunction-associated steatotic liver disease (MASLD) 1, 2
Hepatic steatosis is strongly associated with metabolic syndrome components, including abdominal obesity, insulin resistance/diabetes, hypertension, and dyslipidemia, as stated by the American College of Gastroenterology 1, 2, 4

The accumulation of hepatic triglycerides results from multiple metabolic derangements, including enhanced influx of free fatty acids from adipose tissue lipolysis and chylomicrons from intestinal absorption directly to the liver, as described by the European Association for the Study of the Liver 3
Insulin resistance serves as the central metabolic driver linking adipose tissue dysfunction to hepatic fat accumulation, according to the American Diabetes Association 3

Simple steatosis represents 70-75% of all MASLD cases and is defined as ≥5% hepatic steatosis without evidence of hepatocellular injury, with a minimal risk of progression to cirrhosis, as stated by the American Association for the Study of Liver Diseases 1, 3
Steatohepatitis occurs in 25-30% of MASLD cases and represents a critical pathophysiologic transition characterized by ≥5% hepatic steatosis plus inflammation with hepatocyte injury, with a higher risk of progression to cirrhosis, liver failure, and hepatocellular carcinoma, according to the European Association for the Study of the Liver 1, 3

Macrovesicular steatosis involves large lipid droplets that displace the nucleus and occupy the entire hepatocyte cytoplasm, characteristically associated with metabolic dysfunction, alcohol, obesity, and diabetes, as described by the American College of Gastroenterology 3
The majority of patients with hepatic steatosis present asymptomatically, with 60-80% of patients experiencing no symptoms whatsoever, because the liver capsule lacks pain receptors for stretch or fat accumulation alone, according to the American College of Gastroenterology 5